Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10658161				
Filing Date		2003-09-09				
First Named Inventor Jeyha		an Karaoguz				
Art Unit		2616				
Examiner Name Lynn		Diana Felld				
Attenney Dealest Number		1446711000				

		Kind Code <sup>1</sup>				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	6081523	A 2000-06-27 Merchant et al.		column 2, lines 9-64					
	2 6760778 2004-07-06 Nelson et al.		column 3, lines 24-58; column 10, lines 61-67			10,				
	3	6956824		2005-10-18	Mark et al.		column	2, line 48 t	o column 3, I	ne 2
If you wist	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPL	CATION PUBL	LICATIONS		Remove		
Examiner Initial* Cite No Publication Number Kind Code			nd Publication Name of Patentee or Applicant of cited Document			Releva		Lines where ges or Relev		
								отфров.		
	1							у фроц		
If you wis		dd additional U.S. Publi	shed Ap	plication citation	on information p	olease click the Ad				
If you wis		dd additional U.S. Publi		<u>'                                    </u>	on information p					
If you wisi Examiner Initial*	h to a	dd additional U.S. Publi: Foreign Document Number <sup>3</sup>		FOREIGN PA			d button	Add Remove	or Relevant	Ts

U.S. PATENTS

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10658161			
Filing Date		2003-09-09			
First Named Inventor Jeyha		n Karaoguz			
Art Unit		2616			
Examiner Name Lynn		Diana Feild			
Attaches Dealest North	nr.	14167[1902			

If you wish	h to a	dd add	ditional F	reign Pa	atent Do	ocume	nt citati	on info	ormati	on pleas	e click the	Add butto	η Α	dd		
					NON	N-PAT	ENT LI	TERA	ATURE	DOCU	MENTS		Rer	nove		
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тs									
	1															
If you wis	h to a	dd add	ditional no	n-paten	t literatu	ure doc	cument	citatio	on info	mation	please click	the Add	button	Add		
						E	EXAMI	NER S	SIGNA	TURE						
Examiner	Signa	ture	1								Date Con	sidered				
											ance with N				hrough a	1

1 See Kins Code of USFTO Planto Documents at year, USFTO, CODY or MEPD 910.4. <sup>2</sup> Enter office that issued the cocurrent, by the two-letter code (WPD Standard 513.). <sup>2</sup> The Japanese parted coverents, the relication to the year of the region of the Emperor must proceed the serial number of the papert document. <sup>2</sup> Nicid of Cocurrent by the appropriate symbols as indicated on the document under WPD Standard 51.16 if possible. <sup>3</sup> Applicant is to place a check mark here if English intraguage streamlistion a statistical or statistical or statistical statistical statistics.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10658161		
Filing Date			2003-09-09		
	First Named Inventor Jeyha Art Unit		n Karaoguz		
			2616		
Examiner Name Lynn I		Lynn	Diana Feild		
	Attorney Docket Numb	ec	14167US02		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
X	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement. See 37 CEP 1 07(e)(1)

OR

	That no item of information contained in the information disclosure statement was cited in a communication from a
	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
	after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
_	any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure

1	See	attached	certification	statement.

Fee set forth in 37 CFF	R 1.17 (p) ha	s been submitted h	herewith.

None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

office and adjustice.								
Signature	/ Christopher C. Winslade /	Date (YYYY-MM-DD)	2007-02-28					
Name/Print	Christopher C. Winslade	Registration Number	36.308					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.